136 results
8-K
ATXS
Astria Therapeutics Inc
25 Mar 24
Other Events
7:37am
planned activities and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional
8-K
EX-1.1
ATXS
Astria Therapeutics Inc
4 Mar 24
Entry into a Material Definitive Agreement
5:22pm
or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand … is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also
424B5
ATXS
Astria Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:20pm
to generate sufficient material for our planned STAR-0215 nonclinical and clinical studies;
the potential therapeutic benefits and potential attributes … benefits of any future acquisition, in-license, collaboration or preclinical development activities;
our manufacturing plans, capabilities
8-K
EX-1.1
2coq9 p94h6cx82nwbr
31 Jan 24
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
9:00am
424B5
26atujury20rp8945mq6
31 Jan 24
Prospectus supplement for primary offering
8:59am
8-K
EX-99.1
3tes7c bvj
20 Dec 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-99.1
kkd2ee2run3
13 Nov 23
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
8:06am
8-K
EX-1.1
klmlr
12 Oct 23
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
5:04pm
424B5
3mz7l85 ht
12 Oct 23
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.2
pq57ppwh2a1az
11 Oct 23
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
5:14pm
8-K
sn420 dehgka6
11 Oct 23
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
5:14pm